Abstract bekijken

Deze abstract is toegekend aan sessies
Type presentatieOral presentation
TitelExploring topical losartan for corneal scarring: which scars show regression?
DoelTo describe the first clinical and corneal densitometry outcomes of topical losartan for corneal scarring at our centre (UZ Brussel).
MethodesSeven eyes of seven patients with corneal scars of various aetiologies were treated with topical losartan (0.8 mg/mL, six times daily) on a compassionate-use basis. Patients were evaluated for BCVA, changes in corneal densitometry, and potential local or systemic side effects.
ResultatenFour eyes showed signs of scar regression, with a progressive decrease in corneal densitometry accompanied by an improvement in BCVA. These included scars following bacterial keratitis, a corneal foreign body, post-LASIK keratitis with flap amputation, and herpetic keratitis, with scars having been present for 8-16 months before treatment. Clearing was most pronounced in the anterior layers of the central 6 mm, was already apparent after 3 months, and continued up to 11 months in the eye with the longest follow-up.
Three eyes showed no improvement: longstanding haze following radial keratotomy and LASIK, severe limbal stem cell deficiency, and post-adenoviral scarring, which worsened following withdrawal of topical corticosteroids. No local or systemic side effects were observed in any patient.
ConclusieIn this initial experience, topical losartan was associated with scar regression in four of seven eyes, predominantly in anterior stromal scars of infectious or traumatic origin. Controlled trials are needed to distinguish a true treatment effect from spontaneous scar remodelling over time and to define the indications, optimal dosage, and treatment duration for which topical losartan may be most beneficial.
BelangenverstrengelingNee
Auteurs 1
NaamAMELI
InitialenS
Auteurs 2
NaamKROLO
InitialenI
Auteurs 3
NaamOELLERICH
InitialenS
Auteurs 4
NaamNÍ DHUBHGHAILL
InitialenS
top ^